Sangrix Inc. income statement

In fiscal 2025, Sangrix Inc. reported revenue of $39,495, down 98.6% on the year before, operating income of −$3.0m (a -7574.9% margin) and net income of −$6.5m, or −$84.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sangrix Inc.: income statement, annual
Fiscal year	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025
Revenue	63	101	99	24	80	6	6	3	0
Cost of revenue	58	91	90	22	78	11	11	4	—
Gross profit	5	10	9	2	3	−5	−5	−1	0
General and administrative	1	1	1	3	2	3	3	4	3
Operating income	4	7	−1	−3	−3	−28	−28	−15	−3
Interest expense	1	1	1	0	0	0	0	1	1
Provision for credit losses	0	2	0	0	—	—	0	0	−0
Income before tax	3	4	−1	−4	−4	−28	−28	−18	−4
Income tax	1	1	0	0	−1	—	—	—	—
Net income	2	4	4	−5	−46	3	−28	−18	−7
Diluted EPS	$648.00	$1026.00	$1134.00	—	—	−$1549.80	—	−$1003.41	−$84.84
Diluted shares (average)	—	—	—	—	—	18m	—	—	77m
EBITDA	4	8	0	—	—	—	−23	−14	−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SGRX vs SNTG MI vs SGRX DCM vs SGRX

More: Diversified Financial Services stocks compared, Financials sector, rankings of US companies

Figures from Sangrix Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sangrix Inc.